The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Mergers & AcquisitionsMedium•29 April 2026•

1 min read

Teva to Acquire Emalex Biosciences to Bolster Neuroscience Pipeline

Key Facts

1Teva announced a definitive agreement to acquire Emalex Biosciences to accelerate its pivot to growth strategy.

2The acquisition includes lead asset ecopipam, which demonstrated positive Phase 3 data for Tourette syndrome treatment.

Teva Pharmaceutical Industries Ltd. has entered into a definitive agreement to acquire Emalex Biosciences, a move designed to accelerate its 'Pivot to Growth' strategy. The acquisition centers on the lead asset ecopipam, a first-in-class therapy that has demonstrated positive Phase 3 data for the treatment of Tourette syndrome. This strategic addition significantly strengthens Teva's neuroscience pipeline with a late-stage clinical candidate. An NDA submission for ecopipam is currently anticipated in the second half of 2026. While the financial terms of the deal were not disclosed, the acquisition underscores Teva's focus on high-potential innovative therapies. Analysts view this as a positive step in diversifying the company's specialized medicine portfolio.